Skip to content
stoqly

Jazz Pharmaceuticals

JAZZ Nasdaq Pharmaceuticals Financials FY2016–FY2025

Jazz Pharmaceuticals' revenue rose 4.9% to $4.3 billion in fiscal 2025. Its operating margin was −10.1%, down from 17.6% a year earlier. Free cash flow was $1.3 billion, down 4.5%. It paid out $125 million in dividends and buybacks, 10% of free cash flow. The diluted share count fell 7.6%.

Last close · Oct 23, 2026

$214.00

0.3%
Value it Compare
Revenue Total sales reported in the income statement.
$4.3B
4.9% vs prior year
Operating margin Operating income as a share of revenue.
−10.1%
27.7 pts
Net income Profit after all expenses, interest and tax.
−$356M
163.6%
Free cash flow Cash from operations minus capital spending.
$1.3B
4.5%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
−4.2%
13.3 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$14.9B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
14.6x
On $14.63 EPS (TTM)

About these figures. Jazz's filings tag only its depreciation as its depreciation and amortization total (US$42 million in 2025), leaving out the US$655 million it amortized on acquired products, so depreciation and amortization, EBITDA and the ratios built on it are left blank.

What Jazz Pharmaceuticals does

No business description yet.

Legal name
Jazz Pharmaceuticals plc
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001232524-26-000013
0001232524

Revenue and margins

Jazz Pharmaceuticals had $4.3B of revenue in fiscal 2025, up 4.9% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $1.3B in fiscal 2025, 30.4% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Jazz Pharmaceuticals returned $125M to shareholders in fiscal 2025, 10% of free cash flow. The diluted share count fell 7.6%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Jazz Pharmaceuticals yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$4.0B and divides by 61.0M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 14.6x · peers 27.5x · sector 28.4x.

Balance sheet

Cash, debt and the ratios that show how comfortably Jazz Pharmaceuticals can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $591M$882M$1.5B$2.4B$1.4B
Debt incl. finance leases $6.1B$5.7B$5.7B$6.1B$5.4B
Debt / equity 1.5x1.9x1.5x1.5x1.2x
Interest coverage 1.9x−2.0x17.6x2.3x−1.7x
Current ratio 3.2x2.8x2.2x4.5x1.9x
Quick ratio 1.9x2.0x1.9x4.0x1.7x
Total assets $12.3B$10.8B$11.4B$12.0B$11.7B
Total liabilities $8.3B$7.7B$7.7B$7.9B$7.3B
Shareholders' equity $4.0B$3.1B$3.7B$4.1B$4.3B
Net debt (− = net cash) $5.5B$4.8B$4.2B$3.7B$4.0B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$29.0M

7 insiders

Of sales under plans

92%

$26.7M

DateInsiderTradeSharesPriceValueFiling
Sep 10, 2026 Neena M PatilEVP & Chief Legal Officer Sold plan 1,200 $240.94 $0.3M Form 4
Sep 8, 2026 Renee D GalaPresident & CEO Sold plan 2,000 $243.03 $0.5M Form 4
Sep 1, 2026 Bruce C CozaddDirector Sold plan 6,000 $250.13 $1.5M Form 4
Aug 27, 2026 Robert IannoneEVP, Global Head of R&D & CMO Sold plan 76,921 $249.70 $19.2M Form 4
Aug 3, 2026 Bruce C CozaddDirector Sold plan 6,000 $252.98 $1.5M Form 4
Jul 1, 2026 Bruce C CozaddDirector Sold plan 6,000 $240.47 $1.4M Form 4
Jun 15, 2026 Mark Douglas SmithDirector Sold plan 1,157 $230.55 $0.3M Form 4
Jun 10, 2026 Neena M PatilEVP & Chief Legal Officer Sold plan 1,200 $231.83 $0.3M Form 4
Jun 1, 2026 Bruce C CozaddDirector Sold plan 6,000 $235.12 $1.4M Form 4
May 28, 2026 Neena M PatilEVP & Chief Legal Officer Sold plan 1,192 $236.97 $0.3M Form 4
May 28, 2026 Samantha PearceEVP, Chief Commercial Officer Sold 6,907 $235.41 $1.6M Form 4
May 22, 2026 Rick E WinninghamDirector Sold 2,741 $241.57 $0.7M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✓ ✕
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✓ ✓ ✕
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✕ ✕ ✓
Current ratio rose ✕ ✓ ✕
Share count didn't rise ✕ ✓ ✓
Gross margin rose — — —
Revenue rose relative to assets ✓ ✓ ✕
F-score 5 / 87 / 84 / 8
Accruals ratio −6.1%−7.1%−14.5%
Altman Z'' 2.203.211.63

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Jazz Pharmaceuticals JAZZ $14.9B 4.9% −10.1% 30.4% −4.2% 14.6x 4
Elanco ELAN $11.4B 6.2% — 6.0% −0.1% — 6 Compare →
Amneal Pharmaceuticals AMRX $6.7B 8.1% 13.1% 8.9% 16.1% 41.6x 7 Compare →
Zoetis ZTS $33.8B 2.3% — 24.1% 29.3% 13.4x 8 Compare →
Bausch Health Companies BHC $2.4B 6.7% 17.7% 9.8% 4.5% — 7 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $1.5B $1.6B $1.9B $2.2B $2.4B $3.1B $3.7B $3.8B $4.1B $4.3B
Research and development $162M $198M $227M $300M $335M $506M $591M $850M $884M $783M
Operating income $592M $529M $615M $532M $378M $170M −$65.5M $579M $717M −$430M
Interest expense $27.5M $37.8M $56.7M $62.5M $87.6M $89.9M $32.8M $32.8M $315M $249M
Pretax income $532M $441M $530M $454M $275M −$113M −$373M $298M $470M −$628M
Income tax $135M −$47.7M $80.2M −$73.2M $33.5M $216M −$159M −$120M −$91.4M −$272M
Net income $397M $488M $447M $523M $239M −$330M −$224M $415M $560M −$356M
Diluted EPS $6.41 $7.96 $7.30 $9.09 $4.22 −$5.52 −$3.58 $6.10 $8.65 −$5.84
Diluted shares 0.06B 0.06B 0.06B 0.06B 0.06B 0.06B 0.06B 0.07B 0.07B 0.06B
Cash flow
Cash from operations $592M $693M $799M $776M $900M $779M $1.3B $1.1B $1.4B $1.4B
Capital expenditure $9.7M $28.9M $20.4M $40.1M $15.0M $27.6M $29.0M $24.0M $38.1M $58.8M
Free cash flow $583M $664M $779M $736M $885M $751M $1.2B $1.1B $1.4B $1.3B
Stock-based compensation $98.8M $107M $102M $111M $121M $189M $222M $227M $248M $291M
Acquisitions $1.5B $0.0M $0.0M $0.0M $0.0M $6.2B $0.0M $0.0M $0.0M $0.0M
Share buybacks $278M $98.8M $524M $301M $147M $0.0M $0.1M $270M $311M $125M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $278M $98.8M $524M $301M $147M $0.0M $0.1M $270M $311M $125M
Balance sheet
Cash and short-term investments $426M — $310M $637M $1.1B $591M $882M $1.5B $2.4B $1.4B
Total debt $2.0B $1.6B $1.6B $1.6B $2.1B $6.0B $5.7B $5.7B $6.1B $5.4B
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $6.7M $5.6M $5.5M $5.0M $3.9M
Current assets $748M $968M $1.2B $1.6B $2.8B $2.6B $2.6B $3.4B $4.6B $4.2B
Current liabilities $257M $294M $346M $365M $654M $809M $933M $1.5B $1.0B $2.2B
Inventory $34.1M $43.2M $53.0M $78.6M $95.4M $1.1B $714M $597M $480M $417M
Property and equipment, net $108M $170M $200M $132M $128M $257M $228M $170M $173M $200M
Total assets $4.8B $5.1B $5.2B $5.5B $6.5B $12.3B $10.8B $11.4B $12.0B $11.7B
Total liabilities $2.9B $2.4B $2.4B $2.4B $2.9B $8.3B $7.7B $7.7B $7.9B $7.3B
Shareholders' equity $1.9B $2.7B $2.8B $3.1B $3.7B $4.0B $3.1B $3.7B $4.1B $4.3B
Margins
Operating margin 39.8% 32.7% 32.5% 24.6% 16.0% 5.5% −1.8% 15.1% 17.6% −10.1%
Net margin 26.7% 30.1% 23.6% 24.2% 10.1% −10.7% −6.1% 10.8% 13.8% −8.4%
FCF margin 39.2% 41.0% 41.2% 34.1% 37.4% 24.3% 34.0% 27.9% 33.4% 30.4%
Returns
Return on capital 16.7% — — 13.1% 7.6% 1.9% −0.6% 7.3% 9.1% −4.2%
Return on capital employed 15.5% 11.3% 12.7% 10.6% 6.8% 2.0% −0.6% 5.9% 6.9% −4.2%
Return on equity 22.8% 21.3% 16.4% 17.8% 7.1% −8.7% −6.4% 12.2% 14.3% −8.5%
Return on assets 9.8% 9.8% 8.7% 9.7% 4.0% −3.5% −1.9% 3.7% 4.8% −3.0%
Growth
Revenue growth 12.3% 8.8% 16.8% 14.3% 9.3% 30.9% 18.3% 4.8% 6.1% 4.9%
Net income growth 20.4% 22.9% −8.4% 17.1% −54.4% −238.2% — — 35.0% −163.6%
EPS growth 22.6% 24.2% −8.3% 24.5% −53.6% −230.8% — — 41.8% −167.5%
FCF growth 17.5% 14.0% 17.2% −5.4% 20.2% −15.1% 65.5% −14.1% 27.1% −4.5%
Share count change −1.9% −0.9% −0.2% −6.0% −1.8% 5.6% 4.8% 15.2% −8.4% −7.6%
Financial health
Debt / equity 1.1x 0.6x 0.6x 0.5x 0.6x 1.5x 1.9x 1.5x 1.5x 1.2x
Interest coverage 21.5x 14.0x 10.8x 8.5x 4.3x 1.9x −2.0x 17.6x 2.3x −1.7x
Current ratio 2.9x 3.3x 3.6x 4.5x 4.3x 3.2x 2.8x 2.2x 4.5x 1.9x
Quick ratio 2.8x 3.2x 3.4x 4.3x 4.2x 1.9x 2.0x 1.9x 4.0x 1.7x
Capital allocation
Capex / revenue 0.7% 1.8% 1.1% 1.9% 0.6% 0.9% 0.8% 0.6% 0.9% 1.4%
Stock comp / revenue 6.6% 6.6% 5.4% 5.1% 5.1% 6.1% 6.1% 5.9% 6.1% 6.8%
Payouts / FCF 47.8% 14.9% 67.3% 40.9% 16.6% 0.0% 0.0% 25.3% 22.9% 9.6%
Quality scores
Piotroski F-score 6.0 6.0 7.0 8.0 5.0 3.0 4.0 5.0 7.0 4.0
Altman Z'' 2.5 3.3 3.6 4.1 4.5 1.8 1.6 2.2 3.2 1.6
Accruals ratio −4.8% −4.1% −6.8% −4.7% −11.0% −11.8% −12.9% −6.1% −7.1% −14.5%

Source: SEC EDGAR XBRL filings (CIK 0001232524). Data updated October 16, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open